Analysis reveals potential fatal side effects of glucagon-like peptide-1 agonists for weight loss in obesity, suggesting risks outweigh benefits.
The use of glucagon-like peptide-1 (GLP-1) receptor agonists for managing type 2 diabetes mellitus and obesity has increased significantly in recent years. These medications reduce blood glucose levels by promoting glucose-dependent insulin secretion, inhibiting glucagon release, slowing gastric emptying, and decreasing food cravings.
No takes yet. Share an insight, caveat, or question.
Elsie Burger (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: